back to all

BioProcess International and Cell & Gene Therapy Manufacturing & Commercialization US 2021

Dual Dialogue – Anatomy of an Acquisition: Bayer and RhiaPharmaceutical

  • Overview of the structure of the acquisition, goals, outcomes
  • How the deal came about and COVID-19’s impact on the transaction
  • Bayer’s unique operating model to ensure to successful partnerships within its Cell and Gene Therapy Platform
  • Advancing AAV manufacturing post-acquisition

Speakers:

Sheila Mikhail – CEO & Co-Founder, RhiaPharmaceutical

Marianne De Backer, MBA, PhD – EVP, Head of Strategy, BD&L, Bayer